NightstaRx Ltd (“Nightstar”), a biopharmaceutical company specializing in developing gene therapies for inherited retinal dystrophies, today announced the appointment of Scott M. Whitcup, M.D. to its board of directors. Dr. Whitcup, an expert in developing new treatments for ophthalmological and dermatological diseases, will serve as an independent director to Nightstar.
URL:
www.businesswire.com/news/home/20170502005203/en/NightstaRx-Appoints-Ophthalmology-Industry-Veteran-Scott-Whitcup
URL:
www.businesswire.com/news/home/20170502005203/en/NightstaRx-Appoints-Ophthalmology-Industry-Veteran-Scott-Whitcup
No comments:
Post a Comment